L'iperparatiroidismo Secondario: Linee Guida Per Il Trattamento Ed Effetti a Lungo Termine Della Terapia Con Calcitriolo Endovena

Juppner H. , Abou-Samra A.B. , Freeman M.W. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991; 254: 1024–6.

Urena P. , Segre G.V. , Drueke T.B. Parathyroid hormone receptor. Nephrol Dial Transplant 1994; 9: 593–5.

Zerwekh J.E. Bone metabolism. Seminars in Nephrology 1992; 12: 79–90.

Hruska Ka , Teitelbaum S.L. Renal Osteodistrophy. N Engl J Med 1995; 333: 166–74.

Sutton R.A.L. , Camerol E.C. Renal Osteodystrophy. Patophysiology. Seminars in Nephrology 1992; 12: 91–100.

Chan Y.L. , Furlong T.J. , Cornish C.J. Dialysis osteodystrophy. Medicine 1986; 64: 296–307.

Slatopolsky E. , Delmez J.A. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229–36.

Drueke T.B. , Kubrusly M. Pathogenesis of secondary hyperparathyroidism in chronic renal failure. J Nephrol 1994; 7: 139–47.

Silver J. , Russell J. , Sherwood L.M. Regulation by Vitamin D metabolites of messenger ribonucleic acid for pre-proparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci, USA 1985; 82: 4270–3.

Brown A.J. , Zhong M. , Finch J. , Ritter C. , Slatopolsky E. The roles of calcium and 1,25 dihydroxyvitamin D₃ in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 1995; 136: 1419–5.

Kremer R. , Bolivar I. , Goltzman D. , Hendy G.N. Influence of calcium and 1,25 dihidroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989; 935–41.

Tsukamoto Y. Pathophysiology and treatment of secondary hyperparathyroidism in patients with chronic renal failure. Nephrol Dial Transplant 1995; 10(Suppl 3): 22–4.

Hsu C.H. , Patel S.R. , Young E.N. , Vanholder R. The biological action of calcitriol in renal failure. Kidney Int 1994; 46: 650–62.

Slatopolsky E. , Caglar S. , Pennell J.P. , Toggart J. , Canterbury J. , Reiss E. , Bricker N.S. On the pathogenesis of hyperparathyroidism in chronic experimental insufficiency in the dog. J Clin Invest 1971; 50: 497–9.

Falchetti A. , Bale A.E. , Amorosi A. , Bordi C. , Cicchi P. , Bandini S. , Marx S.J. , Brandi M.L. Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab 1993; 76: 139–44.

Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 1995; 25: 663–79.

Brown E.M. , Gamba G. , Riccardi D. , Lombardi D. , Butters R. , Kifor O. , Sun A. , Hediger M.A. , Litton J. , Hebert S.C. Cloning and characterization of an extracellular Ca²⁺ sensing receptor from bovine parathyroid. Nature 1993; 366: 575–80.

Goodman W.G. , Belin T.R. , Salusky J.B. In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism. Kidney Int 1996; 50: 1834–44.

Felsenfeld A.J. , Llach F. Parathyroid gland function in chronic renal failure. Kidney Int 1993; 43: 771–89.

Slatopolsky E. , Delmez J.A. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11(Suppl 3): 130–5.

Hebert S.C. Extracellular calcium sensing receptor: implication for calcium and magnesum handling in the kidney. Kidney Int 1996; 50: 2129–39.

Rodriguez M. , Felsenfeld A.J. , Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kidney Int 1991; 40: 1063–8.

Rodriguez M. , Martin-Malo A. , Martinez M.E. , Torres A. , Felsenfeld A.J. , Llach F. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney Int 1991; 40: 1055–62.

Yates A.J. , Oreffo R.O.C. , Mayor K. , Mundy G.R. Inhibition of bone resorption by inorganic phosphate is mediated by both reduced osteoclasts formation and decreased activity of mature osteoclasts. J Bone Miner Res 1991; 6: 473–8.

Drueke T.B. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48: 259–72.

Sherrard D.J. , Oh S. , Maloney N. , Andress O. , Coburn J. Renal osteodystrophy: classification, cause and treatment in “Frame B, Potts JJJr eds Clinical Disorders of bone and mineral metabolism”. Excepta Medica, Amsterdam 1983, 254–9.

Gonzalez E.A. , Martin KJ : Renal osteodystrophy. Pathogenesis and management. Nephrol Dial Transplant 1995; 10(Suppl 3): 13–21.

Wang M. , Hercz G. , Sherrard D.J. , Maloney N.A. , Segre G.V. , Pei Y. Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without Aluminum toxicity. Am J Kidney Dis 1995; 26: 836–44.

Dunstan C.R. , Hills E. , Norman A.W. , Bishop J.E. , Mayer E. , Wong S.Y.P. , Johnson J.R. , George C.R.P. , Collette P. , Kalowski S. , Wyndham R. , Lawrence J.R. , Evans RA : The pathogenesis of renal osteodystrophy: Role of vitamin D, aluminum, parathyroid hormone, calcium and phosphorus. Quart J Med 1985; 217: 127–44.

Malberti F. , Surian M. , Ionised calcium changes and parathyroid hormone secretion in hemodiafiltration in relation to substitution fluid content. Nephrol Dial Transplant 1991; 2: 104–7.

Malberti F. , Surian M. , Minetti L. Dialysate calcium concentration decrease exacerbates secondary hyperparathyroidism in dialysis patients given calcium carbonate as a phosphate binder. J Nephrol 1991; 2: 75–81.

Fournier A. , Morinier Ph , Marie A. Adynamic bone disease - Is it actually a disease? Nephrol Dial Transplant 1995; 10: 454–7.

Goodman W. , Ramirez J. , Belin T. , Chon Y. , Gales B. , Segre G.V. , Salusky I.B. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160–6.

Silver J. , Naveh-Many T. , Mayer H. , Schmelzer H.J. , Popovzter M.N. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78: 1296–301.

Fukuda N. , Tanaka H. , Tominaga Y. , Fukagawa M. , Korokawa K. , Seino Y. More severe form of parathyroid hyperplasia is associated with decreased calcitriol receptor density in chronic uremic patients. J Am Soc Neph 1992; 3: 695–9.

Kwan J T.C. , Almond M.L. , Beer J.R. , Noonan K. , Evans S.J.W. , Cunningham J : “Pulse” oral calcitriol in uraemic patients: rapid modification of parathyroid response to calcium. Nephrol Dial Transplant 1992; 7: 829–36.

Reichel H. , Srabo A. , Uhl J. , Pesion S. , Schmutz A. , Schmidt-Gayk H. , Ritz E. Intermittent versus continuous administration of 1.25 dihydroxyvitamin D in experimental renal hyperparathyrodism. Kidney Int 1993; 44: 1259–65.

Quarles L.D. , Yohay D.A. , Carroll B.A. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710–21.

Slatopolsky E. , Weerts C. , Thielan J. , Horst R. , Harter H. , Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1.25 dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136–43.

Gallieni M. , Brancaccio D. Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? I. Medical intervention is the primary option in the treatment of advanced hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 1994, 9: 1816–9.

Cannella G. , Bonucci E. , Rolla D. Evidence of healing of secondary hyperparathyroidism in chronically hemodialysis uremic patients treated with long term intravenous calcitriol. Kidney Int 1994; 46: 1126–32.

Malberti F. , Corradi B. , Cosci P. , Calliada F. , Marcelli D. , Imbasciati E. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. AJKD 1996; 28: 704–12.

Brown E.M. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56: 572–81.

Felsenfeld A.J. , Jara A. , Pahl M. , Bover J. , Rodriguez M. Differences in the dynamics of parathyroid hormone secretion in hemodyalisis patients with marked secondary hyperparathyroidism. J Am Soc Nephrol 1995; 6: 1371–8.

Khosla S. , Ebeling P.R. , Firek A.F. , Burritt M.M. , Kao P.C. , Heath H. Calcium infusion suggests a “set point” abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 1993; 76: 715–20.